Dosing Regimens Before and During Long-Term Treatment with Recombinant Factor VIII FC Fusion Protein (rFVIIIFc) in Children with Severe Haemophilia A: An Updated Analysis of the ASPIRE Study

被引：0
|
作者：
Nolan, B. [1 ]
Young, G. [2 ]
Mahlangu, J. N. [3 ,4 ]
Liesner, R. [5 ]
Pasi, K. J. [6 ]
Yuan, H. [7 ]
Winding, B. [8 ]
Ramirez-Santiago, A. [7 ]
Dumont, J. [7 ]
Lethagen, S. [8 ,9 ]
Glazebrook, D. V. [7 ]
机构：
[1] Our Ladys Childrens Hosp, Dublin, Ireland
[2] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[3] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa
[4] Univ Witwatersrand, Natl Hlth Lab Serv, Johannesburg, South Africa
[5] Great Ormond St Hosp Sick Children, London, England
[6] Barts & London Comprehens Care Ctr, London, England
[7] Biogen, Cambridge, MA USA
[8] Sobi, Stockholm, Sweden
[9] Univ Copenhagen, Copenhagen, Denmark
来源：
HAEMOPHILIA | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P023
引用
收藏
页码：42 / 43
页数：2
相关论文
共 50 条
  • [41] Analysis of bleeding rates in pediatric subjects with target joints and severe hemophilia A receiving prophylaxis with recombinant factor viii fc fusion protein (RFVIIIFC) in kids a-long
    Nolan, B.
    Young, G.
    Rangarajan, S.
    Wang, M.
    Kerlin, B. A.
    Leung, A.
    Tsao, E.
    Glazebrook, D., V
    Pierce, G. F.
    Allen, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 347 - 348
  • [42] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    BLOOD, 2014, 123 (03) : 317 - 325
  • [43] Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG)
    Young, Guy
    Mahlangu, Johnny N.
    Kulkarni, Roshni
    Nolan, Beatrice
    Liesner, Raina
    Pasi, John
    Barnes, Christopher
    Neelakantan, Srividya
    Gambino, Giulia
    Cristiano, Lynda M.
    Barnowski, Christopher
    Pierce, Glenn F.
    Allen, Geoffrey A.
    BLOOD, 2014, 124 (21)
  • [44] KIDS A-LONG: SAFETY, EFFICACY, AND PHARMACOKINETICS OF LONG-ACTING RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) IN PREVIOUSLY-TREATED PAEDIATRIC SUBJECTS WITH HAEMOPHILIA A
    Young, G.
    Mahlangu, J.
    Kulkarni, R.
    Nolan, B.
    Liesner, R.
    Pasi, J.
    Barnes, C.
    Neelakantan, S.
    Gambino, G.
    Cristiano, Lm
    Barnowski, C.
    Pierce, Gf
    Allen, G.
    HAEMATOLOGICA, 2014, 99 : 791 - 791
  • [45] INTERIM DATA FROM A CHART REVIEW STUDY OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS TREATED WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) FOR IMMUNE TOLERANCE INDUCTION
    Klamroth, R.
    Saleh, M.
    Andersson, H.
    Alm, P. E.
    Lethagen, S.
    HAEMOPHILIA, 2021, 27 : 93 - 94
  • [46] HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES IN PEOPLE WITH HEMOPHILIA A (PWHA) FROM THE A-LONG/ASPIRE STUDIES OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC)
    Cockerham, A.
    DasMahapatra, P.
    Tang, W.
    Sajeev, G.
    Yang, H.
    von mackensen, S.
    HAEMOPHILIA, 2022, 28 : 58 - 58
  • [47] INTERIM DATA FROM A CHART REVIEW STUDY OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS TREATED WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) FOR IMMUNE TOLERANCE INDUCTION
    Klamroth, R.
    Saleh, M.
    Schiavulli, M.
    d'Oiron, R.
    Glosli, H.
    Bystricka, L.
    Andersson, H.
    Francke, A.
    Lethagen, S.
    HAEMOPHILIA, 2022, 28 : 65 - 66
  • [48] Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A
    Kulkarni, Roshni
    Ragni, Margaret V.
    Baker, Ross I.
    Pasi, John
    Manco-Johnson, Marilyn J.
    Potts, James
    Brennan, Aoife
    Pierce, Glenn F.
    HAEMOPHILIA, 2014, 20 : 94 - 94
  • [49] A-LONG: results from a Phase 3 study of safety, efficacy, and pharmacokinetics of long-lasting recombinant factor VIII Fc fusion protein (rFVIIIFc)
    Mahlangu, J.
    Powell, J.
    Ragni, M.
    Chowdary, P.
    Josephson, N.
    Pabinger, I
    Hanabusa, H.
    Gupta, N.
    Kulkarni, R.
    Fogarty, P.
    Perry, D.
    Shapiro, A. D.
    Pasi, J.
    Apte, S.
    Krassova, S.
    Jiang, H.
    Li, S.
    Cristiano, L.
    Neelakantan, S.
    Greblikas, F.
    Goyal, J.
    Sommer, J.
    Dumont, J. A.
    Innes, A.
    Nugent, K.
    Brennan, A.
    Luk, A.
    Pierce, G. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 168 - 169
  • [50] Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
    Wang, Michael
    Teresa Alvarez-Roman, Maria
    Chowdary, Pratima
    Quon, Doris V.
    Schafer, Kim
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (07) : 737 - 744
12345